Q3 Earnings Estimate for Xencor Issued By Leerink Partnrs

Key Points

• Leerink Partners raised their Q3 2025 earnings per share (EPS) estimate for Xencor to ($0.74), up from the previous forecast of ($0.76), while the consensus full-year estimate is ($3.68) EPS.
• Xencor reported Q3 earnings of ($0.41), surpassing expectations by $0.37, with revenues of $43.61 million, significantly higher than the forecast of $22.59 million.
• Analyst ratings are mixed, with two analysts issuing sell ratings and seven assigning a buy rating, resulting in an average rating of "Moderate Buy" and a consensus price target of $26.43.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Stock analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for shares of Xencor in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will post earnings per share of ($0.74) for the quarter, up from their prior forecast of ($0.76). The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor's Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($2.76) EPS and FY2026 earnings at ($3.18) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%. The business had revenue of $43.61 million for the quarter, compared to analysts' expectations of $22.59 million. During the same period last year, the business earned ($1.07) EPS. The business's revenue was up 82.4% on a year-over-year basis.

Several other equities analysts have also recently weighed in on XNCR. Wells Fargo & Company dropped their price objective on Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research note on Thursday. William Blair began coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Wedbush reduced their target price on Xencor from $31.00 to $26.00 and set an "outperform" rating for the company in a report on Thursday. Finally, Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Xencor has an average rating of "Moderate Buy" and a consensus price target of $26.43.

Xencor Trading Down 1.2%

Shares of NASDAQ:XNCR opened at $7.23 on Monday. The stock's fifty day simple moving average is $8.67 and its two-hundred day simple moving average is $10.87. Xencor has a 1-year low of $7.07 and a 1-year high of $27.24. The stock has a market cap of $515.64 million, a PE ratio of -3.01 and a beta of 0.89.

Insider Transactions at Xencor

In related news, Director Ellen Feigal sold 2,993 shares of Xencor stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard J. Ranieri sold 2,993 shares of Xencor stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,194 shares of company stock worth $103,209 in the last ninety days. Company insiders own 5.23% of the company's stock.

Institutional Investors Weigh In On Xencor

Several large investors have recently added to or reduced their stakes in XNCR. RTW Investments LP increased its holdings in Xencor by 317.9% in the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after acquiring an additional 1,827,883 shares during the last quarter. BVF Inc. IL increased its holdings in Xencor by 169.3% in the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock worth $52,596,000 after acquiring an additional 1,438,760 shares during the last quarter. Braidwell LP increased its holdings in Xencor by 169.0% in the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company's stock worth $17,617,000 after acquiring an additional 1,040,159 shares during the last quarter. Primecap Management Co. CA increased its holdings in Xencor by 8.6% in the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock worth $103,857,000 after acquiring an additional 776,580 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in Xencor by 452.4% in the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock worth $19,236,000 after acquiring an additional 685,557 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.